NCT05898646 2026-01-13
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
9 trialsNCT07110844 2025-11-19
Teclistamab-Daratumumab in AL Amyloidosis
Columbia University
Phase 2 Recruiting
NCT06649695 2025-09-25
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
European Myeloma Network B.V.
Phase 2 Recruiting
NCT05951049 2025-08-24
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Attralus, Inc.
Phase 2 Recruiting
NCT07079423 2025-07-23
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06935162 2025-05-25
Teclistamab in Previously Treated AL Amyloidosis
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06971380 2025-05-14
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Hadassah Medical Organization
Phase 2 Recruiting
NCT06342466 2024-12-30
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Peking University People's Hospital
Phase 2 Recruiting
NCT06418477 2024-10-01
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Peking University People's Hospital
Phase 2 Recruiting